한글목차

새로운 경로와 신호전달을 이용한 12가지 표적 치료는 종양학 및 항악성 종양 치료의 새로운 시대를 상징하는 결과를 달성했습니다. 이러한 접근법은 암의 신체적, 심리적, 감정적 부담을 경감하는 치료법으로부터 이익을 얻으려는 의약품 개발자의 수가 증가하고 있습니다.

본 보고서에서는 표적 치료제 시장에 대해 조사했으며, 종양학 임상시험의 동향 및 50개의 치료제, 그들이 이용하는 바이오마커에 대해 검증하고, 부문별 동향 등을 정리했습니다.

목차

• 주요 요약
• 재조합 약제의 생태계
• 표적 종양 치료제 시장의 리더
• 종양학 생물 제제-경쟁력에 관한 고려 사항
• 종양 표적 치료제로 승인된 약
• FDA 승인 의약품
• EMA 승인 약
• 트라스투주맙의 바이오시밀러
• EMA 승인된 바이오시밀러
• 바이오시밀러 제품 출시에 대한 소송의 영향
• 표적 종양 치료제-시장 부문
• 유방암
• 대장암
• 혈액암
• 폐암
• 흑색종
• 전이성 위암
• 신경계 암
• 신세포 암
• 요로 상피암
• 공급업체의 경쟁력 평가

영문목차

Targeted Oncology Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug developers, and healthcare marketers with a detailed understanding of the economics, technologies, indications, and commercial opportunities for targeted oncology drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Next-generation Therapeutics

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. This report examines the fifty therapeutic drugs and the biomarkers they utilize.

Here is a Small Sample of the Things You Will Learn:

• How many suppliers have approved mAb products indicated for one or more types of lung cancer?
• Who are the API suppliers for the EMA approved version of Adcetris?
• How many approved biosimilars (FDA and/or EMA) are there for trastuzumab?
• What is the number of EMA approved biosimilars for oncology indications?
• Which Daiichi Sankyo facilities in Japan are used for the API and final manufacture of Enhertu?
• How many approved mAbs are indicated for HER2-positive Breast Cancer?
• Which two mAbs indicated for oncology are supplied as lyophilized powders for reconstitution?
• How many approved oncology mAbs target the CD20 antigen?
• Which supplier is the oncology mAb market leader in terms of revenue?

Table of Contents

• Executive Summary
• The Recombinant Drug Ecosystem
• Targeted Oncology Therapeutics Market Leaders
• Oncology Biologics - Competitive Considerations
• Approved Drugs for targeted Oncology Therapeutics
• FDA-approved Drugs
• EMA-approved Drugs
• Biosimilars of Trastuzumab
• EMA Approved Biosimilars
• The Impact of Litigation on Biosimilar Product Launches
• Target Oncology Therapeutics - Market Segments
• Breast Cancers
• Colorectal Cancers
• Hematology Cancers
• Lung Cancers
• Melanomas
• Metastatic Gastric Cancers
• Neurological Cancers
• Renal Cell Carcinomas
• Urothelial Cancers
• Supplier Competitive Assessments